| 查看: 2296 | 回复: 11 | |||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||||
[交流]
GSK被调查，会对医药行业各个产业链产生什么影响 已有11人参与
|
|||||
| 大家都来深入浅出的分析一下 |
回复此楼» 收录本帖的淘帖专辑推荐
 新药研发必备资料 | 行业动态 |
» 猜你喜欢
调剂
已经有3人回复
-
药学学硕326求调剂
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有215人回复
-
26年博士申请
已经有20人回复
-
求助 苯磷硫胺JP
已经有0人回复
-
100金币 阿莫西林克拉维酸钾片BP药典中提到的克拉维酸聚合物具体结构式是啥？
已经有2人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有0人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有1人回复
-
膳食补充剂合规性交流
已经有0人回复
-
26申博自荐
已经有10人回复
-
一志愿浙大药学求调剂
已经有0人回复
» 本主题相关商家推荐: (我也要在这里推广)
先是网上报纸上骂声一片，然后砖家出来澄清，然后。。。。。就没有然后了。 
4楼2013-07-17 14:33:25
2楼2013-07-17 13:17:45
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
柳叶刀文章，转自丁香园，分析GSK事件，说中国医患问题可能与医生和某些药企的不健康关系有关，请看下文： Doctors and pharma in China The Lancet Doctor—patient relationships in China are in crisis. Doctors have been injured or even killed by patients at work. One of the major drivers might be the unhealthy and unethical relations between many doctors and some drug companies. On July 8, GlaxoSmithKline (GSK) said that they were investigating allegations that its staff had improperly used cash and other incentives to encourage the prescription of onabotulinumtoxin A (Botox) in China. The company added that “inquiries to date have found no evidence of bribery or corruption in relation to our sales and marketing of therapeutic Botox in China.” The Lancet has no evidence to suggest that the allegations against GSK in China are true. However, some observers claim that bribing doctors to boost drug prescriptions by some drug companies is an open secret, and that this alleged practice has compromised the public's trust in doctors. The varieties of unethical relationships that exist between some doctors and some of the drug companies in China are said to range from cash kickbacks, lavish gifts or entertainment, ghost writing services, sponsored supplements in journals, and all-expenses-paid trips. There is real concern that doctors' prescriptions are therefore not based solely on patient need and clinical evidence, but may be biased by commercial interests. The perceived unethical association between physicians and industry in China is worrying, because it inevitably harms patients as well as doctors. It damages the doctor—patient relationship and, ultimately, China's whole health system. The GSK China allegations, although unproven, have clearly rung an alarm bell for China's regulatory authorities to ensure the drug industry promotes products in a responsible, ethical, and professional way. Chinese doctors should rely on evidence-based clinical guidelines to inform their practice, and are in urgent need of guidance on their collaborations with the drug industry in various areas such as patient care, professional education, and research. Furthermore, training for doctors in China on managing their relationships ethically with the drug industry and other organisations should start at medical school and be part of continuing professional education. |
3楼2013-07-17 14:31:18
5楼2013-07-17 19:26:08
10